ArticleEvidence-based complementary and alternative medicine : eCAM2021
Polyphyllin I Inhibits
Article in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Unveiling estrogen's role: a comprehensive review of its impact on skin health and disease.Apoptosis : an international journal on programmed cell death · 2026Review
- Polyphyllins ameliorate imiquimod-induced psoriatic skin barrier disruption and lesions in mice by inhibiting inflammatory infiltration with accelerated recovery effects.Frontiers in immunology · 2026Article
- Regulation of anti-tumour effects of Paris polyphylla saponins via ROS: molecular mechanisms and therapeutic potentials.Frontiers in pharmacology · 2025Review
- Molecular mechanisms of thalidomide effectiveness on COVID-19 patients explained: ACE2 is a new ΔNp63α target gene.Journal of molecular medicine (Berlin, Germany) · 2024Article
- Anti-inflammatory and analgesic properties of Polyphyllin VI revealed by network pharmacology and RNA sequencing.Purinergic signalling · 2024Article
- Saponins ofMolecules (Basel, Switzerland) · 2024Review
- Rhizoma Paridis saponins attenuate Gram-negative bacteria-induced inflammatory acne by binding to KEAP1 and modulating Nrf2 and MAPK pathways.Journal of cellular and molecular medicine · 2024Article
- Current perspectives for metabolomics and lipidomics in dyslipidemia of acne vulgaris: a mini review.Frontiers in medicine · 2024Review
- The updates and implications of cutaneous microbiota in acne.Cell & bioscience · 2023Review
- Inflammasome activation by Gram-positive bacteria: Mechanisms of activation and regulation.Frontiers in immunology · 2023Review
- A narrative review of research progress on the role ofAnnals of translational medicine · 2022Review
- Nontargeted metabolomics to characterize the effects of isotretinoin on skin metabolism in rabbit with acne.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acne vulgaris (AV) is a chronic skin disease involving inflammation of the pilosebaceous units.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.